Cite this: *Mol. BioSyst.*, 2015,
11, 2247

S100A4 and its role in metastasis – simulations of knockout and amplification of epithelial growth factor receptor and matrix metalloproteinases†

Antoine Buetti-Dinh,^{*abc} Igor V. Pivkin^{bd} and Ran Friedman^{*ac}

The calcium-binding signalling protein S100A4 enhances metastasis in a variety of cancers. Despite a wealth of data available, the molecular mechanism by which S100A4 drives metastasis is unknown. Integration of the current knowledge defies straightforward intuitive interpretation and requires computer-aided approaches to represent the complexity emerging from cross-regulating species. Here we carried out a systematic sensitivity analysis of the S100A4 signalling network in order to identify key control parameters for efficient therapeutic intervention. Our approach only requires limited details of the molecular interactions and permits a straightforward integration of the available experimental information. By integrating the available knowledge, we investigated the effects of combined inhibition of signalling pathways. Through selective knockout or inhibition of the network components, we show that the interaction between epidermal growth factor receptor (EGFR) and S100A4 modulates the sensitivity of angiogenesis development to matrix metalloproteinases (MMPs) activity. We also show that, in cells that express high EGFR, MMP inhibitors are not expected to be useful in tumours if high activity of S100A4 is present.

Received 28th April 2015,
Accepted 28th May 2015

DOI: 10.1039/c5mb00302d

www.rsc.org/molecularbiosystems

1 Introduction

S100A4 belongs to the S100 family of low-molecular weight calcium-binding proteins that transmit cellular signals through conformational changes mediated by Ca^{2+} and other ions.¹ There are more than 20 known S100 proteins in humans, many of which are tissue- or cell-type specific and have altered expression in some types of cancer.^{2–4} S100A4 has been reported to be involved in several different processes related to cancer progression.⁵ In cancer tissues, S100A4 has been found in cytoplasm, nucleus and also in the extracellular matrix.⁵ The protein is expressed by a variety of cell types in the tumour microenvironment of human breast cancer⁶ and its increased expression is associated with human colorectal adenocarcinomas.^{7,8} Early studies have shown that increased levels of S100A4 induce a metastatic phenotype in rodent models of mammary carcinogenesis.^{9,10} Moreover, knockdown of S100A4 suppresses cell migration and metastasis in osteosarcoma

cell lines¹¹ and reduces cell growth and motility in human pancreatic cancer cells.¹² S100A4 is preferentially expressed in cells with motile phenotype⁵ and it influences motility^{13–15} and invasion^{16–18} *via* interactions with myosin IIA (myosin-9) and MMPs, respectively. Several studies report that S100A4 promotes angiogenesis.^{19,20} Tumours with elevated levels of S100A4 show high vessel density in breast cancer²¹ where S100A4 stimulates angiogenesis *via* interactions with annexin II²⁰ and osteopontin (OPN).²² MMPs and their natural inhibitors, tissue inhibitors of matrix metalloproteinases (TIMPs), play a major role in these processes by regulating the degradation of the extracellular matrix and consequently facilitating (or preventing) invasion and tissue remodelling. Interactions between S100A4, MMPs and epithelial–mesenchymal transition (EMT) target genes such as β -catenin and E-cadherin have been shown in different systems.^{4,5,23} It has also been verified in several models that S100A4 knockdown reduces the expression of MMP genes, thereby suppressing cell migration.^{18,24} Extracellular S100A4 appears to be involved in EGFR signalling by interacting with EGFR/Erbb2 ligands.²⁵ These interactions have been shown to enhance S100A4 expression²⁶ suggesting potential regulation through positive feedback.⁴ The possibility of interactions between p53 and S100A4 has previously been debated^{27,28} and is supported by recent findings showing that S100A4 interacts with p53 and MDM2, indicating that S100A4 promotes p53 degradation.²⁹

^a Department of Chemistry and Biomedical Sciences, Linnæus University, Kalmar, Sweden. E-mail: antoine.buetti@lnu.se, ran.friedman@lnu.se

^b Institute of Computational Science, Faculty of Informatics, Università della Svizzera Italiana, Lugano, Switzerland

^c Centre of Excellence for Biomaterials Chemistry, Linnæus University, Kalmar, Sweden

^d Swiss Institute of Bioinformatics, Lausanne, Switzerland

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c5mb00302d

Despite abundant data on S100A4 and its interacting partners, the regulatory aspects underlying the bridging role that S100A4 represents between metastasis and angiogenesis is still poorly understood. Consequently, the development of therapies aiming to block targeted components of the S100A4 network is hampered by insufficient understanding of its complex compensatory signalling. Here we apply network analysis to predict the effect of (combined) targeted inhibition *in silico* and to identify the mechanisms and network's control points that are relevant for the development of successful therapeutic strategies.

2 Methods

2.1 S100A4 network

A signalling network model for S100A4 based on the experimental evidence mentioned previously together with a set of derived networks corresponding to the different biological situations described in the "Results" section were used to study the effects of gene knockout and overexpression on the S100A4 network and to investigate potential therapeutic strategies by selective inhibition of some of the network's components.

2.2 Modelling framework

We used a quantitative phenomenological modelling framework composed of modules for numerical simulation and analysis to study biological networks in a flexible way (details are found in the companion article³⁰). The method allows to efficiently carry out sensitivity analysis of biological networks and thereby to identify key control points where the effect of addition, removal and inhibition of components that can have a high impact on the

endpoint(s). Modifications can easily be applied to pre-existing settings, and new entries can be rather easily integrated in the model. Consequently, the effect of gene knockout, overexpression and other perturbations can be tested without a detailed mechanistic knowledge of the underlying interactions. Parameter ranges can be adapted according to available knowledge: from several orders of magnitude in case of poorly characterized processes, to a much narrower range if suggested by accurate experimental information. The system's response to parameter variation reveals the role of different components. The results are summarized through graphical representations (principal component analysis (PCA) and sensitivity landscape plots). Through this procedure, we can identify control points in the network such as switches (sensitive regions) where small changes yield large effects on the biological outcome (*e.g.*, cell dissociation) or buffers (paths that are robust with respect to external perturbations).

3 Results

We carried out simulations of the S100A4 network as presented in Fig. 1. Thereby, we investigated the combined effects of gene knockout and targeted inhibition by removing nodes and constraining the activities of certain components of the network. Simulation of such modified systems enables the characterization of the effects of therapeutic interventions in quantitative terms and the identification of potential resistance mechanisms. In the following sections we detail the *in silico* response of a series of cases where the network model of S100A4 (see scheme in Fig. 1)

Fig. 1 The interaction network of S100A4. S100A4 is coloured yellow and can be present in the interior and exterior cellular space. Blue nodes represent cytoskeletal proteins. Purple nodes represent the direct players for regulation and degradation of extracellular matrix proteins. Cyan-circled nodes represent important regulators in modulating the S100A4-mediated effect on the network. Red nodes summarize converging effects from the different pathways according to biological knowledge for cellular dissociation from the extracellular matrix (CellDiss) and capillary growth (CapGrowth). These are the endpoints involved in the pathological metastatic process. Activation and inhibition between nodes is denoted with $\rightarrow$ and $\dashv$, respectively.

is modified by removal or alteration of the most relevant network components (S100A4, MMPs, EGFR, NF- κ B).

3.1 Simulations with a larger network

The S100A4 network scheme represented in Fig. 1 is an approximation of the main processes influencing cell dissociation and capillary growth. To ensure that the outcome of our simulations is independent of the set up of the network, we tested our approach with an extended S100A4 network (see Fig. ESI 1 (ESI[†])). The extended network has been enlarged according to references^{31–38} and includes 9 additional nodes and 13 additional reactions compared to the network represented in Fig. 1 (this corresponds to an increase of 60% and 42% for nodes and reactions, respectively). We note that in robustness tests, a network able to tolerate a variation of 5–20% in the number of the nodes is considered highly robust.^{39,40} The results obtained with the enlarged network (see Fig. ESI 2 (ESI[†])) are consistent with the ones that correspond to the scheme of Fig. 1 (compare Fig. ESI 2 (ESI[†]) with Fig. 2 and 3 of the companion article³⁰). This indicates that the effects of S100A4 on the network are reproducible over a wide range of network components considered in the network.

3.2 S100A4 knockout

We emulated S100A4 gene knockout by removing S100A4 (intra- and extracellular) from the node list and consequently all in- and out-pointing edges. This way, we mimic cancer cells that are devoid of S100A4 activity or treatment by an effective S100A4 inhibitor, which may become available in the future.^{41,42} We then ran simulations with different levels of EGFR activity. Compared to simulations of the complete

network set with an initially low S100A4 basal activity level, in response to increasing EGFR activity, the sensitivity to MMPs and TIMPs increases moderately for cell dissociation and strongly for capillary growth whereas their corresponding steady-state levels are not significantly affected (see Fig. 2). We have previously reported that, in the presence of S100A4, the sensitivity of capillary growth to MMPs and TIMPs showed a complex pattern, where two stable regions (insensitive to MMPs and TIMPs activities) could be observed. Knocking out S100A4 abolished this pattern. Instead, a general decrease in sensitivity to MMPs and TIMPs was observed. Interestingly, both MMPs and TIMPs can adopt broader range of activities when S100A4 is knocked down, whereas only the activity of MMPs is shifted to higher values in response to increased levels of EGFR (see the projections on the plane corresponding to variable EGFR activity in Fig. 2).

3.3 Inhibition of MMPs

MMPs are released by the tumour microenvironment and play an important role in cancer progression by enhancing cell motility and invasion.^{6,43,44} Inhibition of metalloproteinases has been the focus of diverse therapeutic strategies against cancer.⁴⁵ We therefore simulated MMPs inhibition by eliminating from the full network model the links that influence its activity and constraining its steady-state level to a constant low value of 0.0001. We then followed on the variation of S100A4 in combination with increasing EGFR (see section “S100A4 knockout”). TIMPs do not influence the system (see Fig. ESI 3 (ESI[†])). In the absence of MMPs, S100A4 activity levels correlate to cell dissociation and capillary growth. MMPs inhibition increases the sensitivity of capillary growth to variations, whereas that of

Fig. 2 S100A4 knockout. Sensitivity of cell dissociation (A) and capillary growth (B). Upper, convex sensitivity surfaces are calculated in response to variation of MMPs activity levels ($\epsilon_{\text{MMPs}}^X = \frac{\Delta[\ln(X)]}{\Delta[\ln(\text{MMPs})]}$ where $X = \text{CellDiss}$ (A) or $X = \text{CapGrowth}$ (B)) and are shown in light colours. Lower, concave surfaces are calculated in response to variation of TIMPs activity levels ($\epsilon_{\text{TIMPs}}^X = \frac{\Delta[\ln(X)]}{\Delta[\ln(\text{TIMPs})]}$ where $X = \text{CellDiss}$ (A) or $X = \text{CapGrowth}$ (B)) and are shown in dark colours. Projections in the lower planes represent the activity ranges (steady-state values) of MMPs and TIMPs (higher projections, colour code corresponding to the sensitivity surfaces in response to varying MMPs). The lowest projection represents the steady-state values of cell dissociation at low EGFR activity. EGFR levels correspond to basal activity values set to low = 0.001, medium = 0.01 and high = 0.1. Note that an increase in the activity of EGFR results in constraining the activity of MMPs (but not TIMPs) to higher values (see arrows next to the middle surface).

Fig. 3 Inhibition of MMPs. Sensitivity of cell dissociation (A) and capillary growth (B) as a function of S100A4 activity. EGFR levels correspond to basal activity values set to low = 0.001, medium = 0.01 and high = 0.1. The barrier separates the system into two states, one where targeted treatment may help (controlled regime) and one where it cannot (metastatic regime).

cell dissociation remains unaltered. In addition, a sensitivity barrier (*i.e.*, a peak of the calculated sensitivity function) between low and high steady-state values of both variables CellDiss and CapGrowth can be observed. The barrier decreases proportionally to EGFR activity (see Fig. 3).

3.4 S100A4 knockout and inhibition of MMPs

We subsequently combined the two approaches described in sections “S100A4 knockout” and “Inhibition of MMPs” by simulating systematic variation of EGFR while modulating the activity of NF- κ B (TIMPs do not influence the system as in section “Inhibition of MMPs”, see Fig. ESI 4 (ESI[†])). This combined approach appears to successfully counter both cell dissociation and capillary growth as indicated by lower steady state levels (see Fig. ESI 4 (ESI[†])) and an increase in the sensitivity as a function of EGFR activity (see Fig. 4). The latter is an indication that the system can be under control. However, the system is still able to sustain a regime dictated by high levels of cell dissociation and capillary growth through (very)

high activity of EGFR (Fig. ESI 4 (ESI[†])). It is not clear if such high values of EGFR can be maintained in cells. Thus, it may be possible to limit or postpone metastasis by MMP inhibitors in the absence of S100A4. A sensitivity barrier between low and high steady-state values of CellDiss and CapGrowth variables is inversely proportional to the activity of NF- κ B.

3.5 Inhibition of EGFR-mediated feedback of S100A4

EGFR-mediated feedback of S100A4 has previously been suggested.^{4,25,26} We consequently simulated the system without the interactions between EGFR and S100A4 (both intra- and extracellular). Inhibiting EGFR increases the sensitivity of cell dissociation and capillary growth consequently improving controllability. At the same time it restricts MMPs and TIMPs steady-state to higher ranges (Fig. 5A and B compared to Fig. 5C and D). With and without the EGFR-mediated feedback of S100A4, an increase in the concentration of biologically active S100A4 causes a homogeneous reduction of sensitivity without affecting the corresponding steady-state values. In addition,

Fig. 4 Combination of S100A4 knockout and inhibition of MMPs. Sensitivity of cell dissociation (A) and capillary growth (B). NF- κ B levels correspond to basal activity values set to low = 0.001, medium = 0.01 and high = 0.1.

Fig. 5 The effect of inhibition of EGFR-mediated feedback of S100A4. Sensitivity landscapes of cell dissociation (A) and capillary growth (B) with inhibited feedback loop. The sensitivity landscapes of cell dissociation (C) and capillary growth (D) with intact feedback of S100A4 are also shown for comparison.

EGFR inhibition was sufficient to abolish the formation of multiple regions sensitive to capillary growth separated by the near-zero sensitivity boundaries as observed in Fig. 5D, highlighting the role of the EGFR-mediated positive feedback in the co-regulation between S100A4 and EGFR reported previously⁴ and observed in the PCA applied to steady-state and sensitivity data as a group of variables including S100A4 together with EGFR and NF- κ B closely linked to the variable representing capillary growth (Fig. ESI 8 and Text ESI 1.5 (ESI[†])).

3.6 The pattern of multiple sensitivity regions depends on EGFR activity

We further investigated in more details the phenomenon described in the previous section. Besides increasing sensitivity of cell dissociation and restricting MMPs and TIMPs to higher steady-state ranges, a more complex effect is observed in the alteration of the capillary growth sensitivity landscape. While no relevant change in CellDiss and CapGrowth steady-state values is observed, the multistable character of the system presenting multiple sensitive regions that rearrange as a function

of S100A4 activity (see Fig. 5D) disappears, yielding a homogeneous surface over a wider sensitivity range (Fig. 5B). A more detailed representation of EGFR-mediated feedback as applied to the sensitivity of capillary growth is shown in Fig. 6. Multistable equilibria are observed at intermediate activity of S100A4 (Fig. 6A). This branched pattern of states characterised by low sensitivity disappears with inhibition of EGFR-mediated feedback (Fig. 6B) and consistent behaviour is observable in the PCA.

4 Discussion

S100A4 is used as a prognostic marker for metastatic tumours. This small, metastasis promoting protein occupies a central place in a dense interaction network of cancer-related processes. Extensive experimental evidence connects S100A4 to angiogenesis, invasion and enhanced cell motility in a variety of cancers. In spite of the abundant data, integration of current knowledge in a therapeutic context presents a challenge. Several S100A4-interacting partners have been used as targets for therapeutic intervention in the past, but the intricacy of such

Fig. 6 Remodelling of the near-zero sensitivity pattern with increasing S100A4. Areas of low capillary growth sensitivity (comprised between sensitivity values of ± 0.005 to $\pm 0.5\%$) to varying MMPs and TIMPs are represented with active (A) and inhibited (B) EGFR-mediated feedback of S100A4. Different levels of S100A4 cause a reorganization of the areas of low sensitivity that display a branched pattern in the presence of active EGFR (indicated by black arrows).

signalling pathways often leads to drug resistance. Quantitative insights are therefore necessary to understand dosage and compensation effects that emerge from complex signalling interactions. Using network-based simulations and biologically relevant yet simplifying assumptions, we could investigate the combined effects of inhibition without detailed knowledge of the interactions between the nodes. Nonlinear effects resulting from feedbacks, pleiotropy and redundancy could therefore be taken into consideration in a global context.

4.1 EGFR-mediated Feedback of S100A4 is responsible for multistable buffering patterns

The knockout of S100A4 or the inhibition of the EGFR-mediated feedback of S100A4 causes the loss of the multistable buffering pattern previously observed in the full S100A4 network (Fig. 5 and 6). We showed that the positive feedback plays a crucial role in the co-regulation between S100A4 and EGFR, reported earlier.^{25,26} This behaviour was further investigated by focussing on a near-zero sensitivity section at intermediate activity of S100A4 (Fig. 5). A branched, broad buffering area insensitive to MMPs and TIMPs fluctuations disappears upon removal of EGFR (Fig. 6). Therefore, in the presence of EGFR, S100A4's activity stabilizes the state of reduced capillary growth (corresponding to low activity of MMPs, see Fig. 5D and 6A). This suggests a positive contribution of S100A4 to the stability of a physiological phenotype in the presence of functional EGFR. Conversely, high S100A4 makes high angiogenic regimes less sensitive to MMPs and TIMPs in the network with inhibited EGFR (Fig. 5B *versus* Fig. 5D). This shows that S100A4 can have opposite effects on the network dynamics upon inactivation of a single network component. The inactivation of EGFR-mediated feedback of S100A4 is sufficient to reverse the effect of S100A4 turning it into a stabilizing factor for low angiogenic regimes without modifying the corresponding steady-state activity profile. In addition, the described near-zero, branched sensitivity pattern shown in Fig. 6 supports potential multistable states of the system due to fluctuations of MMPs basal activity.

The system can assume intermediate MMPs activity ranges bridging the two extreme regions of the MMPs activity ranges therefore facilitating (stochastic) transitions between controlled and metastatic regimes. Tumour cells containing different concentrations of proteolytically active MMPs may therefore serve as basis for the emergence of cell heterogeneity. This effect is also observable in the PCA of the steady-state activity where a variable cluster including S100A4 and EGFR is most closely associated to capillary growth at intermediate S100A4 activity (Fig. 4 of the companion article³⁰). Similar variable clusters are observed in the absence of EGFR where, however, different activity of S100A4 does not affect their relative distances: the pattern is nearly identical over the different activity ranges of S100A4 (Fig. ESI 8 (ESI[†])). PCA of sensitivity values also indicates impairment of the co-regulation between S100A4 and capillary growth in the absence of EGFR.

4.2 Simulations of targeted treatment

The network model was investigated in a therapeutic-oriented manner by selectively removing or inhibiting components based on the existing biological knowledge. Quantitative information from simulated knockout, targeted inhibition and their combined effect enabled the characterization of potential targets for therapeutic intervention and mechanisms leading to drug resistance. We therefore investigated the effect of blocking MMPs and/or S100A4 together with methodical variation of key network components such as EGFR, S100A4 and NF- κ B. While S100A4 knockout accentuated the effect on the cell dissociation sensitivity landscape observed earlier by reduced S100A4 activity in the intact network, capillary growth sensitivity followed instead a similar trend as with EGFR inhibition. This confirmed the role of the EGFR-mediated positive feedback loop mentioned in "EGFR-mediated feedback of S100A4 is responsible for multistable buffering patterns" in co-regulating S100A4 and EGFR. In addition, across a higher sensitivity barrier with respect to the intact network, the system devoid of S100A4 was still susceptible to assume pathological regimes due to a very high activity of EGFR. This reveals the presence of a compensation

mechanism that drives the system to a similar behaviour as in the presence of S100A4. It remains to be seen if high levels of active EGFR are indeed observed in tumours, or if tumours devoid of S100A4 and treated by a combination of MMPs and EGFR inhibitors fail to form metastases. Furthermore, when inhibition of MMPs was simulated, the system revealed complete insensitivity to TIMPs on the one hand and steady-state alteration of cell dissociation and capillary growth with respect to the intact network on the other. High activity of S100A4 has in this case too the potential to drive the system beyond a sensitivity barrier determined by EGFR to pathological regimes and consequently compensate for inhibited MMPs. Combination of S100A4 knockout with inhibition of MMPs further impairs both cell dissociation and capillary growth through barriers in the sensitivity landscape that increase sensitivity to EGFR's activity and at the same time decrease the steady-state levels of cell dissociation.

Interestingly, network modifications involving EGFR-mediated S100A4 translocation did not significantly alter the steady-state levels of cell dissociation and capillary growth but had a strong effect on their sensitivity profile. This effect was marked by an overall increase of the relative sensitivity barrier separating low from high activity levels. In contrast, modifications involving MMPs (inhibited alone or in combination with other targets) resulted in a decrease of cell dissociation and an increase of capillary growth steady-state with respect to the intact network.

5 Conclusions

We used a steady-state simulation method to study a network leading to metastasis in solid cancers (breast cancer in particular), where the key interactions involve S100A4, various MMPs and their tissue inhibitors, EGFR and NF- κ B. Through selective knockout or inhibition of the network components, we have studied potential therapeutic interventions. Our results suggest that while MMP inhibitors are not expected to be useful in tumours that express S100A4, they can otherwise be useful as inhibitors of metastasis as long as the concentration of active EGFR in the cells is not too high. Other potential therapies have also been discussed. Overall, our approach is useful to decide on experiments that involve regulation of biological networks.

Acknowledgements

We acknowledge Prof. Gunhild M. Mælandsmo together with her staff for helpful discussions and Kirill Lykov for technical help with computational infrastructures. The calculations were performed on resources provided by the Swedish National Infrastructure for Computing (SNIC) at Lunarc, centre for scientific and technical computing for research at Lund University and by the Swiss National Supercomputing Centre (CSCS). I.V.P. acknowledges the support from Swiss National Science Foundation and Swiss Platform for Advanced Scientific Computing. This work was supported by Holcim Foundation

(Switzerland, to AB) and Crafoord Foundation (Sweden, grant application numbers 20120856 and 20130787, to RF).

References

- 1 L. Santamaria-Kisiel, A. C. Rintala-Dempsey and G. S. Shaw, *Biochem. J.*, 2006, **396**(2), 201–214.
- 2 I. Salama, P. S. Malone, F. Mihaimeed and J. L. Jones, *Eur. J. Surg. Oncol.*, 2008, **34**(4), 357–364.
- 3 L. J. Sparvero, D. Asafu-Adjei, R. Kang, D. Tang, N. Amin, J. Im, R. Rutledge, B. Lin, A. A. Amoscato, H. J. Zeh and M. T. Lotze, *J. Transl. Med.*, 2009, **7**, 17.
- 4 H. Chen, C. Xu, Q. Jin and Z. Liu, *Am. J. Cancer Res.*, 2014, **4**(2), 89–115.
- 5 K. Boye and G. M. Mælandsmo, *Am. J. Pathol.*, 2010, **176**(2), 528–535.
- 6 T. Cabezon, J. E. Celis, I. Skibshoj, J. Klingelhöfer, M. Grigorian, P. Gromov, F. Rank, J. H. Myklebust, G. M. Mælandsmo, E. Lukanidin and N. Ambartsumian, *Int. J. Cancer*, 2007, **121**, 1433–1444.
- 7 K. Takenaga, H. Nakanishi, K. Wada, M. Suzuki, O. Matsuzaki, A. Matsuura and H. Endo, *Clin. Cancer Res.*, 1997, **3**, 2309–2316.
- 8 S. Gongoll, G. Peters, M. Mengel, P. Piso, J. Klemphauer, H. Kreipe and R. von Wasielewski, *Gastroenterology*, 2002, **123**, 1478–1484.
- 9 B. R. Davies, M. P. Davies, F. E. Gibbs, R. Barraclough and P. S. Rudland, *Oncogene*, 1993, **8**, 999–1008.
- 10 M. Grigorian, N. Ambartsumian, A. E. Lykkesfeldt, L. Bastholm, F. Elling, G. Georgiev and E. Lukanidin, *Int. J. Cancer*, 1996, **67**, 831–841.
- 11 M. Fujiwara, T. G. Kashima, A. Kunita, I. Kii, D. Komura, A. E. Grigoriadis, A. Kudo, H. Aburatani and M. Fukayama, *Tumour Biol.*, 2011, 611–622.
- 12 T. Tabata, N. Tsukamoto, A. A. Fooladi, S. Yamanaka, T. Furukawa, M. Ishida, D. Sato, Z. Gu, H. Nagase, S. Egawa, M. Sunamura and A. Horii, *Biochem. Biophys. Res. Commun.*, 2009, **390**, 475–480.
- 13 R. R. Bowers, Y. Manevich, D. M. Townsend and K. D. Tew, *Biochemistry*, 2012, **51**(39), 7740–7754.
- 14 S. Tarabykina, T. R. Griffiths, E. Tulchinsky, J. K. Mellon, I. B. Bronstein and M. Kriajevska, *Curr. Cancer Drug Targets*, 2007, **7**, 217–228.
- 15 Z. H. Li and A. R. Bresnick, *Cancer Res.*, 2006, **66**(10), 5173–5180.
- 16 J. Zhang, D. L. Zhang, X. L. Jiao and Q. Dong, *Eur. Rev. Med. Pharmacol. Sci.*, 2013, **17**(17), 2372–2382.
- 17 W. Jia, X. J. Gao, Z. D. Zhang, Z. X. Yang and G. Zhang, *Eur. Rev. Med. Pharmacol. Sci.*, 2013, **17**(11), 1495–1508.
- 18 M. Saleem, M. H. Kweon, J. J. Johnson, V. M. Adhami, I. Elcheva, N. Khan, B. Bin Hafeez, K. M. Bhat, S. Sarfaraz, S. Reagan-Shaw, V. S. Spiegelman, V. Setaluri and H. Mukhtar, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**(40), 14825–14830.
- 19 N. Ambartsumian, J. Klingelhöfer, M. Grigorian, C. Christensen, M. Kriajevska, E. Tulchinsky, G. Georgiev,

- V. Berezin, E. Bock, J. Rygaard, R. Cao, Y. Cao and E. Lukanidin, *Oncogene*, 2001, **20**(34), 4685–4695.
- 20 A. Semov, M. J. Moreno, A. Onichtchenko, A. Abulrob, M. Ball, I. Ekiel, G. Pietrzynski, D. Stanimirovic and V. Alakhov, *J. Biol. Chem.*, 2005, **280**, 20833–20841.
- 21 S. de Silva Rudland, L. Martin, C. Roshanlall, J. Winstanley, S. Leinster, A. Platt-Higgins, J. Carroll, C. West, R. Barraclough and P. Rudland, *Clin. Cancer Res.*, 2006, **12**, 1192–1200.
- 22 G. Berge, S. Pettersen, I. Grotterød, I. J. Bettum, K. Boye and G. M. Mælandsmo, *Int. J. Cancer*, 2011, **129**, 780–790.
- 23 M. Schneider, J. L. Hansen and S. P. Sheikh, *J. Mol. Med.*, 2008, **86**(5), 507–522.
- 24 K. Bjørnland, J. O. Winberg, O. T. Odegaard, E. Hovig, T. Loennechen, A. O. Aasen, O. Fodstad and G. M. Mælandsmo, *Cancer Res.*, 1999, **59**(18), 4702–4708.
- 25 J. Klingelhöfer, H. D. Møller, E. U. Sumer, C. H. Berg, M. Poulsen, D. Kiryushko, V. Soroka, N. Ambartsumian, M. Grigorian and E. M. Lukanidin, *FEBS J.*, 2009, **276**(20), 5936–5948.
- 26 R. Hernan, R. Fasheh, C. Calabrese, A. J. Frank, K. H. Maclean, D. Allard, R. Barraclough and R. J. Gilbertson, *Cancer Res.*, 2003, **63**(1), 140–148.
- 27 M. Grigorian, S. Andresen, E. Tulchinsky, M. Kriajevska, C. Carlberg, C. Kruse, M. Cohn, N. Ambartsumian, A. Christensen, G. Selivanova and E. Lukanidin, *J. Biol. Chem.*, 2001, **276**(25), 22699–22708.
- 28 G. Berge and G. M. Mælandsmo, *Amino Acids*, 2011, **41**(4), 863–873.
- 29 L. M. Orre, E. Panizza, V. O. Kaminsky, E. Vernet, T. Gräslund, B. Zhivotovsky and J. Lehtiö, *Oncogene*, 2013, **32**(49), 5531–5540.
- 30 A. Buetti-Dinh, I. V. Pivkin and R. Friedman, *Mol. BioSyst.*, under review.
- 31 E. Aréchaga-Ocampo, N. Villegas-Sepulveda, E. Lopez-Urrutia, M. Ramos-Suzarte, C. Lopez-Camarillo, C. Perez-Plasencia, C. H. Gonzalez-de la Rosa, C. Cortes-Gonzalez and L. A. Herrera, Biomarkers in Lung Cancer: Integration with Radiogenomics Data, in *Oncogenomics and Cancer Proteomics – Novel Approaches in Biomarkers Discovery and Therapeutic Targets in Cancer*, ed. C. Lopez, 2013 ISBN: 978-953-51-1041-5, InTech, DOI: 10.5772/53426, <http://www.intechopen.com/books/oncogenomics-and-cancer-proteomics-novel-approaches-in-biomarkers-discovery-and-therapeutic-targets-in-cancer/biomarkers-in-lung-cancer-integration-with-radiogenomics-data>.
- 32 T. G. Whitsett, A. Richer, J. Friel, V. Carson and L. Inge, *Pharmacogenomics Pers. Med.*, 2015, 63.
- 33 D. Hanahan and R. A. Weinberg, *Cell*, 2000, **100**, 57–70.
- 34 K. Hirota, M. Murata, T. Itoh, J. Yodoi and K. Fukuda, *J. Biol. Chem.*, 2001, **276**, 25953–25958.
- 35 A. A. Habib, S. Chatterjee, S. K. Park, R. R. Ratan, S. Lefebvre and T. Vartanian, *J. Biol. Chem.*, 2001, **276**, 8865–8874.
- 36 S. S. Sidhu, R. Nawroth, M. Retz, H. Lemjabbar-Alaoui, V. Dasari and C. Basbaum, *Oncogene*, 2010, **29**, 4145–4156.
- 37 K. Boye, J. M. Nesland, B. Sandstad, M. Haugland Haugen, G. M. Mælandsmo and K. Flatmark, *Br. J. Cancer*, 2012, **107**, 667–674.
- 38 S. Sarkar, R. Swiercz, C. Kantara, K. A. Hajjar and P. Singh, *Gastroenterology*, 2011, **140**, 583–595.
- 39 R. Albert, H. Jeong and A. L. Barabasi, *Nature*, 2000, **406**, 378–382.
- 40 H. Jeong, B. Tombor, R. Albert, Z. N. Oltvai and A. L. Barabasi, *Nature*, 2000, **407**, 651–654.
- 41 V. N. Malashkevich, N. G. Dulyaninova, U. A. Ramagopal, M. A. Liriano, K. M. Varney, D. Knight, M. Brenowitz, D. J. Weber, S. C. Almo and A. R. Bresnick, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**(19), 8605–8610.
- 42 U. Sack, W. Walther, D. Scudiero, M. Selby, J. Aumann, C. Lemos, I. Fichtner, P. M. Schlag, R. H. Shoemaker and U. Stein, *Mol. Biol. Cell*, 2011, **22**(18), 3344–3354.
- 43 B. Schmidt-Hansen, D. Orns, M. Grigorian, J. Klingelhöfer, E. Tulchinsky, E. Lukanidin and N. Ambartsumian, *Oncogene*, 2004, **23**(32), 5487–5495.
- 44 L. Salvatori, F. Caporuscio, A. Verdina, G. Starace, S. Crispi, M. R. Nicotra, A. Russo, R. A. Calogero, E. Morgante, P. G. Natali, M. A. Russo and E. Petrangeli, *PLoS One*, 2012, **7**(2), e31467.
- 45 C. M. Overall and O. Kleifeld, *Nat. Rev. Cancer*, 2006, **6**(3), 227–239.